109 related articles for article (PubMed ID: 7633307)
1. Minimal residual disease in leukaemia.
Kumar L
Natl Med J India; 1995; 8(4):150-3. PubMed ID: 7633307
[No Abstract] [Full Text] [Related]
2. Minimal residual disease detection in human leukemias: biologic and clinical significance.
Saglio G
Acta Haematol Pol; 1995; 26(2 Suppl 1):19-24. PubMed ID: 7653231
[TBL] [Abstract][Full Text] [Related]
3. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
[TBL] [Abstract][Full Text] [Related]
4. Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromes.
Haferlach C; Rieder H; Lillington DM; Dastugue N; Hagemeijer A; Harbott J; Stilgenbauer S; Knuutila S; Johansson B; Fonatsch C
Genes Chromosomes Cancer; 2007 May; 46(5):494-9. PubMed ID: 17311250
[TBL] [Abstract][Full Text] [Related]
5. [GPI-PLD gene exon14 polymorphisms of leucocyte in peripheral blood from healthy persons and leukemia patients].
Yang ZY; Huang H; Tang JH; Yu H; Wang YD; Xiang XY
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):28-31. PubMed ID: 16562670
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.
Kurzrock R; Kantarjian H; Wetzler M; Estrov Z; Estey E; Troutman-Worden K; Gutterman JU; Talpaz M
Exp Hematol; 1993 Jan; 21(1):80-5. PubMed ID: 8417962
[TBL] [Abstract][Full Text] [Related]
7. The detection and significance of minimal residual disease in chronic myeloid leukemia.
Radich JP
Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting.
Chang H; Sutherland R; Nayar R; Li D; Kamel-Reid S; Mile MA; Messner H; Lipton J
Cancer Genet Cytogenet; 2004 Jul; 152(2):146-8. PubMed ID: 15262435
[TBL] [Abstract][Full Text] [Related]
9. Concomitant chronic myeloid leukemia and chronic lymphocytic leukemia: a different clonal origin shown by molecular cytogenetics.
Gozzetti A; Bocchia M; Crupi R; Calabrese S; Pirrotta MT; Raspadori D; Defina M; Algeri R; Lauria F
Cancer Genet Cytogenet; 2008 Jan; 180(1):83-4. PubMed ID: 18068541
[No Abstract] [Full Text] [Related]
10. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.
Engelhardt M; Mackenzie K; Drullinsky P; Silver RT; Moore MA
Cancer Res; 2000 Feb; 60(3):610-7. PubMed ID: 10676644
[TBL] [Abstract][Full Text] [Related]
11. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease using clonospecific primers for CDRIII in patients with acute B lymphocytic leukemia with or without Philadelphia chromosome: possibility of clinical application as a tool for improving prognosis.
Maeda Y; Horiuchi F; Morita S; Matsuda M; Shirakawa C; Masaki H; Koyama A; Hamazaki H; Fujimoto T; Irimajiri K
Exp Hematol; 1994 Aug; 22(9):881-7. PubMed ID: 8062887
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease in chronic myeloid leukaemia.
Cross NC
Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
[TBL] [Abstract][Full Text] [Related]
14. Argyrophilic nucleolar organizer regions (AgNORs) in relation to p53 and bcl-2 protein expression in leukemia patients.
Klobusická M; Kusenda J; Babusíková O
Neoplasma; 2003; 50(6):408-15. PubMed ID: 14689061
[TBL] [Abstract][Full Text] [Related]
15. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
[TBL] [Abstract][Full Text] [Related]
16. Synthetic small interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia(+) acute myeloid leukaemia.
Koldehoff M; Steckel NK; Beelen DW; Elmaagacli AH
Clin Exp Med; 2006 Mar; 6(1):45-7. PubMed ID: 16550344
[No Abstract] [Full Text] [Related]
17. D104N polymorphism in endostatin, an angiogenesis inhibitor, in acute and chronic myeloid leukaemia.
Nascimento H; Lourenço GJ; Ortega MM; Yamaguti GG; Costa FF; Lima CS
Leuk Res; 2007 Aug; 31(8):1158-9. PubMed ID: 17067672
[No Abstract] [Full Text] [Related]
18. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
19. Chronic lymphocytic leukemia developing in a patient with chronic myeloid leukemia: evidence of distinct lineage-associated genomic events.
Gargallo P; Cacchione R; Chena C; Dupont J; Garay G; Riveros D; Larripa I; Slavutsky I
Cancer Genet Cytogenet; 2005 Aug; 161(1):74-7. PubMed ID: 16080961
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
